BioXcel Therapeutics, Inc. 8K

BioXcel Therapeutics amended its Oaktree-led credit facility on July 31, 2026 to defer a June 2026 payment to August 31, 2026, lower minimum liquidity, add a requirement to secure an acceptable refinancing or sale transaction by August 10, 2026, and impose temporary compensation and other covenants in favor of the lenders.

On July 31, 2026, BioXcel Therapeutics, Inc. entered into an Eleventh Amendment to its April 19, 2022 Credit Agreement and Guaranty with Oaktree Fund Administration, LLC as administrative agent and the various Oaktree-affiliated and other lenders, which (i) further defers the loan payment originally due June 30, 2026 (previously deferred to July 31, 2026) to August 31, 2026, with a required payment of $9,016,914.47 plus accrued interest and fees on that date, (ii) reduces the minimum liquidity covenant from $7.5 million to $6.25 million effective from the Eleventh Amendment effective date, (iii) requires the company and its obligor affiliates by August 10, 2026 to enter into definitive agreements for an “Acceptable Transaction” that either repays the credit facility in full or provides alternative capital solutions on terms acceptable to the Majority Lenders, (iv) restricts new or modified compensation and certain out-of-ordinary-course payments to officers and employees through August 31, 2026 without Majority Lender consent, and (v) includes borrower reaffirmations, broad releases of lender-related claims, and an obligation to pay lenders’ fees and expenses associated with the amendment.

Filing Facts

CIK

1720893

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-089436

Alert Tier

7